First Tracks Biotherapeutics, Inc.
TRAXNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $1.52B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $14.72$49.91
- Volume (live)
- -
- Avg. volume (3M)
- 1.11M
First Tracks Biotherapeutics (TRAX) Stock Price & Financial Analysis
First Tracks Biotherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $43.21 - $46.08 |
|---|---|
| 52-Week High | $49.91 |
| 52-Week Low | $14.72 |
| Open | $43.33 |
| Volume (last close) | 618.04K |
| Average Volume (3M) | 1.11M |
| 50-Day MA | $38.94 |
|---|
| Market Cap | 1.52B |
|---|---|
| Shares Outstanding | 35.00M |
| Price to Book (P/B) | 9.02 |
| EV/EBITDA | -7.34 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 27, 2026. Data sources and methodology
First Tracks Biotherapeutics at a Glance
As of the Oct 27, 2026 close, First Tracks Biotherapeutics (TRAX) has a market capitalization of $1.52B.
As of its latest reported balance sheet, it holds $168.02M in cash and securities against $4.33M of debt, a net cash position of $163.69M.
First Tracks Biotherapeutics does not currently pay a dividend.
At $45.38 (the Oct 27, 2026 close) it sits near the top of its 52-week range of $14.72 to $49.91.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $74.20, 63.5% above the Oct 27, 2026 close.
Frequently Asked Questions About First Tracks Biotherapeutics
What is the current stock price for TRAX?
As of the Oct 27, 2026 close, TRAX stock trades at $45.38. The 52-week range is $14.72–$49.91, with a day range of $43.21–$46.08.
What is the P/E ratio for TRAX?
The P/E ratio (Price-to-Earnings) for TRAX is shown in the Key Statistics section. This valuation metric helps compare First Tracks Biotherapeutics, Inc. to industry peers.
Does TRAX pay dividends?
First Tracks Biotherapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for TRAX?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for TRAX is Buy. The average 12-month price target is $74.20, a 63.5% upside from the Oct 27, 2026 close of $45.38.
What is the market cap of TRAX?
As of the Oct 27, 2026 close, First Tracks Biotherapeutics's market capitalization is $1.59B, classifying it as a small-cap company. First Tracks Biotherapeutics operates in the Healthcare sector within the Biotechnology industry.